Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rho-associated kinase-Human corneal endothelial cells
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Arctic Vision
Deal Size : $35.0 million
Deal Type : Licensing Agreement
Details : Arctic Vision will develop and market ActualEyes’ AE-101, for the treatment of corneal endothelial dysfunction in Greater China and South Korea. ARVN901 (AE-101) is a novel cell-injection therapy developed using cultured hCECs combined with a ROCK inhi...
Brand Name : AE101
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 14, 2021
Lead Product(s) : Rho-associated kinase-Human corneal endothelial cells
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Arctic Vision
Deal Size : $35.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?